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Background: During the last two decades, resection of colorectal liver metastases (CLM) in selected
patients has become the standard of care, with 5-year survival rates of 25–58%. Although a substantial
number of actual 5-year survivors are reported after resection, 5-year survival rates may be inadequate
to evaluate surgical outcomes because a significant number of patients experience a recurrence at some
point.
Objectives: This study aimed to analyse longterm results and prognostic factors in liver resection for
CLM in patients with complete 10-year follow-up data.
Methods: A total of 369 patients who underwent liver resection for CLM between 1985 and 1998 were
identified from a bi-institutional database. Postoperative deaths and patients with extrahepatic disease
were excluded. Clinicopathological prognostic factors were analysed using univariate and multivariate
analyses.
Results: The sample included 309 consecutive patients with complete 10-year follow-up data. Five- and
10-year overall survival rates were 32% and 23%, respectively. Overall, 93% of recurrences occurred
within the first 5 years of follow-up, but 11% of patients who were disease-free at 5 years developed later
recurrence. Multivariate analysis demonstrated four independent negative prognostic factors for survival:
more than three metastases; a positive surgical margin; tumour size >5 cm, and a clinical risk score >2.
Conclusions: Five-year survival rates are not adequate to evaluate surgical outcomes of patients with
CLM. Approximately one-third of actual 5-year survivors suffer cancer-related death, whereas patients
who survive 10 years appear to be cured of disease.
Keywords
colorectal cancer, liver metastasis, disease-free survival
Received 1 August 2009; accepted 11 November 2009
Correspondence
James Garden, Department of Clinical and Surgical Science (Surgery), Royal Infirmary of Edinburgh,
University of Edinburgh, Edinburgh EH16 4SA, UK. Tel: + 44 131 242 3614. Fax: + 44 131 242 3617.
E-mail: ogarden@staffmail.ed.ac.uk
Introduction
During the last two decades, resection of colorectal liver
metastases (CLM) in selected patients has been increasingly
accepted as the reference standard treatment.1 This is a conse-
quence of the improved safety of liver resection and the increasing
evidence in favour of an associated survival benefit. The evidence
for such survival benefit is based on retrospective studies report-
ing actuarial 5-year survival rates of 25–58% for patients under-
going resection compared with patients treated with
chemotherapy (6–12 months) or untreated patients (12–20
months).2–9 However, the real cure rate associated with liver resec-
tion remains poorly defined as previous studies have restricted
their follow-up to 5 years.
Five-year survival rates may be insufficient as evidence of an
adequate oncological outcome and in fact there is increasing
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evidence that a significant number of patients experience recur-
rence after 5 years.10,11 In order to evaluate the real curative efficacy
of surgery, longer-term follow-up data are necessary. The aim of
this study was to analyse longterm outcomes of surgery, in terms
of prognostic factors and incidence of late recurrences, in patients
with CLM and complete 10-year follow-up data.
Materials and methods
Between September 1985 and May 1998, 369 patients treated with
curative intent surgery for CLM were identified at two major
hepatobiliary centres: the Royal Infirmary of Edinburgh (RIE),
Edinburgh, UK, and the Department of Surgery–Liver Unit, Sci-
entific Institute San Raffaele (HSR), Milan, Italy.
Prior to surgery, all patients were evaluated with a baseline
history and physical examination, serum laboratory tests, and
appropriate imaging studies (computed tomography [CT] or
magnetic resonance imaging [MRI] scan of the abdomen and
pelvis, and chest radiography or CT) at the discretion of the
treating doctor. Patients were deemed to have resectable disease
only if it was anticipated that the metastases could be completely
resected, at least two adjacent liver segments could be spared,
vascular inflow and outflow could be preserved, and the volume of
the liver remaining after resection would be adequate.
The follow-up included clinical examination, estimation of
serum carcinoembryonic antigen (CEA) level, and CT or MRI
scanning at 6 months and then yearly. Follow-up was performed
by assessing the records of the respective institutions for labora-
tory, interventional and pathological data, and by postal or
telephone contact with the local referring clinician (surgeon or
oncologist) for patients residing at a distance from the hospital.
Data relating to the patients’ well-being and oncological status
were pursued until the endpoints of demonstrable tumour
recurrence, cancer-specific survival and overall survival were
established.
Data collection
Standard demographic and clinicopathological data were col-
lected on each patient, including data on sex, age and CEA level, as
well as on treatment-related variables including history of chemo-
therapy. Data were also collected on tumour characteristics. Spe-
cifically, data were collected on primary tumour location, stage
(American Liver Tumour Study Group modified Tumor-Node-
Metastasis [TNM] classification) and presentation (synchronous
vs. metachronous). The number, size and distribution of the
hepatic metastases were also recorded. Resection was classified as
less than a hemi-hepatectomy (e.g. segmentectomy or subsegmen-
tectomy), hemi-hepatectomy or extended hepatectomy (more
than five liver segments). Date of last follow-up, vital status and
recurrence-related information were collected. With regard to
recurrence, both the sequence and overall pattern of recurrence
were noted. Information regarding the location and number of
lesions, as well as the disease-free interval from the date of the
initial operation to the development of recurrent disease was
recorded.
Disease-specific survival (DSS) was calculated from the time of
initial hepatectomy until cancer-related death. For the purposes of
analysis, recurrences were classified as intrahepatic only, extrahe-
patic only, or intra- and extrahepatic. Patients with synchronous
extrahepatic disease at the time of liver resection or with incom-
plete 10-year follow-up were excluded from the study. Patient
survival analysis was also performed with stratification by the
clinical risk score (CRS). This is a staging system that grades risk
for recurrence by five clinical parameters.1 The five clinical criteria
are: nodal status of the primary tumour; a disease-free interval
from the primary to discovery of the liver metastases of <12
months; more than one tumour; preoperative CEA level >200 ng/
ml, and size of the largest tumour >5 cm. Each criterion was
assigned 1 point, and the total points were used to correlate to
the clinical outcomes of each patient after liver resection. The
total score has been shown to be highly predictive of longterm
outcomes.1,12,13
Statistical analyses
Summary statistics were obtained using established methods and
presented as percentages or median values. Disease-specific sur-
vival was calculated from the time of initial hepatectomy until
cancer-related death.
Rates for DSS and time to recurrence were estimated using the
non-parametric product limit method (Kaplan–Meier).14 Differ-
ences in recurrence and survival were examined using the log-
rank test. Factors associated with overall survival were examined
using univariate and multivariate Cox regression analyses. The
hazard ratio and 95% confidence intervals (CIs) were estimated
and a P-value of <0.05 was considered significant. All statistical
analyses were performed using spss Version 16.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
Patient characteristics
A total of 369 patients underwent liver resection for CLM during
the study period. Thirty patients (8.1%) were lost to follow-up
before 10 years and thus were excluded from the study. Five
patients (1.4%) who died in the perioperative period and 25
patients (6.8%) with synchronous extrahepatic disease were also
excluded from the study. Therefore, analysis focused on a cohort
of 309 patients with a median age at the time of resection of 65
years (range 22–85 years) and complete 10-year follow-up. Com-
plete information on the use of adjuvant chemotherapy was not
available for all patients. Of the 72 patients for whom the chemo-
therapy regimen was known, some patients were treated with
5-fluorouracil-based monotherapy (n = 44) and others received
hepatic artery infusional chemotherapy (n = 28). Table 1 shows
the clinicopathological features of the 309 patients in the study.
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Disease-specific and disease-free survival
One-, 3-, 5- and 10-year overall survival rates for the entire cohort
of patients were 82.2%, 45.3%, 32% and 23.6%, respectively
(Fig. 1). The median survival was 49 months (range 1–250
months) and the survival curve reached a plateau after 10 years
from the time of hepatic resection. This plateau represents 71
actual 10-year survivors, demonstrating a minimum cure rate of
23%. Disease status at last follow-up identified 69 patients (22%)
with no evidence of disease, two patients alive with disease, 220
patients (71%) dead as a result of disease and 18 patients (6%)
dead as a result of other causes.
One-, 3-, 5- and 10-year DSS rates were 78.4%, 47.3%, 36.1%
and 29%, respectively (Fig. 2). The majority of the recurrences
occurred within the first 5 years of follow-up, but nine of the 77
patients (12%) who were disease-free at 5 years developed late
recurrence.
Isolated liver recurrence was observed in 111 patients (36%), of
whom 36 (32%) underwent liver re-resection. Of these 36
re-resected patients, 11 patients are alive without any recurrence;
in the remaining 25 patients isolated hepatic recurrence was
observed in 12 patients, isolated extrahepatic recurrence in eight
and associated hepatic and extrahepatic recurrence in five
patients. Four of the 25 patients with liver recurrence underwent
a third hepatic resection and one patient is alive without any
recurrence.
Forty-five patients (15%) experienced associated hepatic and
extrahepatic recurrence. Isolated extrahepatic recurrence was
recorded in 64 patients (21%). Of 32 patients with lung
metastases, seven underwent re-resection and one is alive and
disease-free.
Ten-year survivors
Disease status at last follow-up identified 69 patients (22%) with
no evidence of disease, and two patients alive with disease. The
median follow-up for the 10-year survivors was 146months (range
124–243 months). Fifty-six of the 71 (79%) actual 10-year survi-
Table 1 Characteristics of patients and survival (n = 309)
n, (%) 5-year
survival, %
10-year
survival, %
Age >70 years
No 227 (73) 35 21
Yes 82 (27) 32 19
Gender
Male 195 (63) 33 20
Female 114 (37) 36 25
Primary tumour
Colon 268 (87) 37 20
Rectum 41 (13) 31 18
Primary tumour
Node-negative 111 (36) 42 21
Node-positive 198 (64) 31 17
Metastases presentation
Synchronous 79 (25) 32 14
Metachronous 230 (75) 43 20
Disease-free interval
<12 months 125 (41) 35 14
>12 months 184 (59) 42 20
Largest tumour size
<5 cm 178 (58) 39 19
>5 cm 131 (42) 29 6
CEA, median
<24 ng/ml 170 (55) 37 20
>24 ng/ml 139 (45) 22 4
CEA
<200 ng/ml 246 (79) 37 20
>200 ng/ml 40 (21) 22 4
n, (%) 5-year
survival, %
10-year
survival, %
Extent of resection
Wedge resection 100 (32) 36 24
Segmentectomy (1) 65 (21) 35 21
Segmentectomy (>1) 68 (22) 37 17
Extra right
hepatectomy
46 (15) 32 16
Extra left
hepatectomy
30 (10) 30 18
Number of lesions
1 155 (50) 38 25
2 67 (21) 36 20
3 45 (15) 32 15
4 42 (14) 27 10
Surgical margin
Negative 275 (89) 38 22
Positive 34 (11) 26 11
Blood loss >2000 cc
No 275 (90) 37 20
Yes 34 (10) 33 15
Portal clamping
No 130 (46) 38 18
Yes 149 (54) 32 15
Portal clamping
<30 min 79 (53) 31 16
>30 min 70 (47) 28 13
Adjuvant chemotherapy
No 207 (74) 34 18
Yes 72 (26) 36 19
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vors remained disease-free after a single hepatectomy. In 11 (16%)
patients, recurrences were confined to the liver; these patients
underwent a second liver resection and two (3%) of them subse-
quently underwent a third liver resection. In two patients recur-
rences were limited to the lungs. One patient experienced an
additional pulmonary recurrence and is alive with disease. One
patient had recurrence involving both the liver and the lung. This
patient underwent second resections of both liver and lung and
remains alive with disease secondary to additional pulmonary
recurrences. Of the 10-year survivors, 93% (66 of 71) had liver-
only disease throughout their course.
The CRS was found to be predictive of longterm outcome (P <
0.001). Ten-year survival rates for CRS of 0, 1, 2 and 3 were 41.3%,
37.6%, 21.4% and 0%, respectively.
Factors influencing probability of survival
Univariate analysis identified six factors that were significantly
predictive of survival (Table 2), namely: node status of the
primary tumour; preoperative CEA level >200 ng/ml; tumour size
>5 cm, more than three lesions; surgical margin status, and CRS
>2. Multivariate analysis on these factors revealed that a preop-
erative CEA level >200 ng/ml, tumour size >5 cm, surgical margin
status and CRS >2 remained independent predictors of poor
survival (Table 2).
Discussion
Hepatic resection of CLM has become the treatment of choice for
selected patients after resection of the primary colorectal cancer.
Despite variability in criteria for patient selection, 5-year survival
rates have ranged consistently from 25% to 58%2–9 and these data
have supported the clinical contention that cure may be achieved
in some of these patients. However, the longterm outcome of
patients undergoing hepatic resection for CLM remains contro-
versial. In fact, most studies report actual 5-year survival statistics
as evidence of an adequate oncological outcome, although some
5-year survivors show evidence of disease recurrence.1,15–17
Longer survival rates are rarely available in the literature. Some
authors report 10-year survival rates of 20–25%, but these are
estimated actual data.1,17 The only two published series with com-
plete follow-up data report 10-year survival rates of 17% and 16%,
respectively.10,11 However, surgical resection of CLM should nowa-
days be focused on disease-free survival as a true measure of
curative therapy, rather than on overall survival time, as it is known
thatmodern systemic chemotherapymay prolong survival beyond
2 years in the palliative setting.18 In the literature, the recurrence
rate after liver surgery for colorectal metastases is approximately
60–90%.1 Themajority of recurrences usually occurwithin the first
3 years of follow-up,1,16 but no clear data are available about later
recurrences. Tomlinson et al. analysed 10-year outcomes and late
recurrences: 73 of 102 5-year survivors died of cancer-related
causes, and 23% of these had a documented first recurrence after 5
years.10 Unfortunately, the data for 19% of the 5-year survivors
were inadequate to evaluate the timing of recurrence. Similarly,
Viganò et al. reported that 88% of recurrences occurred within the
first 3 years and 98% within the first 5 years. However, 50% of
patients who were disease-free at 3 years and 15% of patients who
were disease-free at 5 years later developed recurrences.11 No recur-
rence was observed after 10 years of follow-up.
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Figure 1 Kaplan–Meier plot of observed overall survival rates
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Figure 2 Kaplan–Meier plot of observed disease-specific survival
rates
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It is evident in the current series that the DSS curve reaches a
plateau only after 10 years. Of the 71 actual 10-year survivors
representing this plateau in the curve, no patient suffered a
cancer-related death. The time-point from liver resection at which
disease-specific death becomes an extremely rare event should be
used to consider a patient as cured. In the current series, most of
the recurrences occurred within the first 5 years. However, 11%
of patients who were disease-free at 5 years later developed
recurrences.
Currently, there is no consensus regarding the extent and
frequency of follow-up after hepatic resection for CLM. Most
patients undergo serial serum CEA level tests and CT scans for
5 years following liver resection in an attempt to identify early
recurrence that may be amenable to further resection for cure.19
The results of this study confirm that late recurrence (>5 years)
may occur and for some of these patients re-resection may still
be possible. In the present series, three patients who were
disease-free at 5 years and developed liver recurrences under-
went liver resection and two of them were alive at the 10-year
follow-up.
There is increasing evidence that modern systemic adjuvant
chemotherapy may prolong survival in patients with CLM.1,18
However, patients included in our study underwent liver resec-
tion before the introduction of modern chemotherapeutic
agents such as irinotecan, oxaliplatin and bevacizumab. During
the time period of this study, the only available perioperative
chemotherapy agents were fluorouracil-based and had minimal
efficacy. Given the marginal benefit associated with fluorouracil-
based therapies and the fact that patients with extrahepatic
disease were not included, this cohort represents an ideal group
of patients in which to investigate the true benefit of liver resec-
tion of CLM.
Previously determined prognostic factors were also analysed
in the hope of identifying factors that might negate the potential
for longterm survival and cure. However, no single preoperative
or postoperative prognostic factor was sufficient to negate
this potential. The presence of four or more tumours, CEA
>200 ng/ml and large tumours were associated with an unfavour-
able prognosis. This supports data from previous studies.2,9,12
Similarly, the presence of a positive margin was also associated
with significantly reduced survival rates.Microscopic involvement
of surgical resection margins has emerged in many publications
as a significant factor of poor prognosis.2,20–22 Tomlinson et al.
reported that no patients who survived 10 years had a positive
margin.10 However, in the present series five patients with a micro-
scopic positive margin were disease-free at the 10-year follow-up.
This finding may be secondary to the different techniques used for
liver parenchyma transection. In this series, the ultrasonic dissec-
tor was used routinely. In comparison with the clamp crushing
technique, the ultrasonic dissector aspirates approximately 5 mm
of normal liver parenchyma during transection of liver paren-
chyma, overestimating the positive margin rate. This potential
overestimation of the proportion of R1 resections has been
recently reported by several authors.23–25 The results of this study
confirm that clinicopathological factors such as tumour number,
tumour size and surgical margin should no longer be used to
categorically exclude patients from consideration for surgical
resection, but possibly to select patients for aggressive chemo-
therapy programmes.
Given that no single risk factor precluded the possibility of
longterm survival and cure, the CRS was analysed. A CRS 2
predicted a better survival compared with the higher scores. No
patient with a CRS >3 was alive at the 10-year follow-up. These
results confirm that the CRS is a valid staging system to predict
outcome following liver resection for CLM.
In conclusion, cure after liver resection of CLM should be
defined as 10-year survival after initial hepatectomy. Five-year
survival rates are not adequate to evaluate the surgical outcomes
Table 2 Prognostic factors associated with 10-year overall survival
Prognostic factor Univariate Multivariate
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Rectal primary tumour 0.69 0.47–1.31 0.450 – – –
Primary LN metastasis 1.36 0.88–2.12 0.045 – – –
Synchronous metastasis 0.80 0.50–1.21 0.490 – – –
CEA >200 ng/ml 1.73 0.89–2.46 0.022 1.81 1.80–3.60 0.040
Hepatic lesion >5 cm 1.51 0.86–2.76 0.045 1.64 0.65–1.98 0.039
Number lesions >3 1.57 0.81–2.77 0.021 1.61 1.10–2.49 –
Blood loss >2000 ml 0.69 0.43–1.11 0.221 – – –
Positive surgical margin 1.89 1.63–3.12 0.021 1.48 1.20–3.25 0.045
Hemi-hepatectomy 0.79 0.49–1.48 0.455 – – –
Adjuvant chemotherapy 0.54 0.39–1.14 0.542
Portal clamping 0.61 0.41–1.21 0.452
CRS >2 3.19 1.63–4.12 <0.001 2.76 1.85–4.55 0.001
CI, confidence interval; LN, lymph node; CEA, carcinoembryonic antigen; CRS, clinical risk score
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of patients with CLM as recurrence is possible after this period,
although re-resection may still be an option for some of these
patients. On investigation of previously determined unfavourable
prognostic factors, no single preoperative or postoperative factor
was sufficiently discriminatory to negate the potential for cure
after resection.
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